Status:
COMPLETED
Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism
Lead Sponsor:
Bispebjerg Hospital
Conditions:
Hirsutism
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
Split-face investigation of the efficacy of applying Eflornithin cream twice daily for six months after a period with six laser treatments for hair removal.
Detailed Description
Background: Unwanted facial hair growth is a serious problem for 5-15% of all women winch affects their quality of life. In Denmark patients are offered six laser treatments covered by the public heal...
Eligibility Criteria
Inclusion
- 18 years or older
- habile, understands Danish
- moderate to severe hirsutism prior to laser treatments
- succeeded minimum five laser treatments
- intact skin with no severe adverse events to laser treatments
- record of current medication and androgen hormone blood profile available
- Use of safe anti-conception (fertile women)
Exclusion
- Pregnant or lactating
- allergy toward the content of Eflornithin cream
- Concomitant use of immunosuppressive therapy
- Dementia, psychiatric disease, alcoholic
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT01817894
Start Date
January 1 2012
End Date
October 1 2013
Last Update
December 2 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatological Dep Bispebjerg Hospital
Copenhagen NV, Copenhagen, Denmark, 2400